指南与共识哮喘

哮喘口服糖皮质激素减量的国际专家共识:一项德尔菲研究

Expert Consensus on the Tapering of Oral Corticosteroids for the Treatment of Asthma. A Delphi Study.
指南 / 共识 · Am J Respir Crit Care Med · 2021-01-01

专家一致认为所有接受维持性OCS治疗的哮喘患者均应尝试减量并个体化调整节奏与速度,但未就肾上腺功能不全的评估方法达成统一共识。

要点

  • 所有接受维持性OCS治疗的哮喘患者均应尝试减量,并个体化调整减量节奏与速度。
  • 需重视识别OCS相关个体化不良反应,但肾上腺功能不全的评估方法尚未达成统一共识。
  • 医患共同决策被视为OCS减量过程中的重要目标。

核心结论

  • 专家共识支持对所有接受维持性OCS治疗的哮喘患者尝试减量,并个体化调整减量节奏与速度。
  • 专家未就肾上腺功能不全的统一评估方法达成共识,提示该领域存在不确定性,需进一步研究。

主要发现

  • 专家就OCS的适当使用、减量、不良反应识别及医患共同决策等方面形成了多条推荐与指导。
  • 专家一致认为OCS减量应尝试用于所有接受维持性OCS治疗的哮喘患者,并个体化调整减量节奏与速度。
  • 专家未就肾上腺功能不全的评估方法达成统一共识。
  • 医患共同决策被视为减量过程中的重要目标。

关键数值与推荐

  • 共识阈值定义为≥70%同意率。
  • 专家一致认为所有接受维持性OCS治疗的哮喘患者均应尝试减量,并个体化调整减量节奏与速度。
  • 医患共同决策被视为OCS减量过程中的重要目标。
  • 未就肾上腺功能不全的统一评估方法达成共识。

临床怎么用

  • 对接受维持性OCS治疗的哮喘患者,应尝试启动减量并个体化调整减量节奏与速度。
  • 在减量过程中重视识别OCS相关不良反应,并推动医患共同决策。
  • 肾上腺功能不全的评估方法尚缺乏统一共识,临床需结合具体情况谨慎处理。

局限性

  • 肾上腺功能不全等部分OCS使用方面未达成共识,提示专家间存在不确定性,需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rationale: There is a need to minimize oral corticosteroid (OCS) use in patients with asthma to prevent their costly and burdensome adverse effects. Current guidelines do not provide recommendations for OCS tapering in patients with asthma.Objectives: To develop expert consensus on OCS tapering among international experts.Methods: A modified Delphi method was used to develop expert consensus statements relating to OCS use, tapering, adverse effects, adrenal insufficiency, and patient-physician shared decision-making. Initial statements proposed by experts were categorized, filtered for repetition, and presented back to experts over three ranking rounds to obtain consensus (≥70% agreement).Measurements and Main Results: One hundred thirty-one international experts participated in the study, and 296 statements were ranked. Numerous recommendations and guidance regarding appropriate OCS use were established. Experts agreed that OCS tapering should be attempted in all patients with asthma receiving maintenance OCS therapy, with personalization of tapering rhythm and speed. The importance of recognizing individual adverse effects was also established; however, a unified approach to the assessment of adrenal insufficiency was not reached. Shared decision-making was considered an important goal during the tapering process.Conclusions: In this Delphi study, expert consensus statements were generated on OCS use, tapering, adverse-effect screening, and shared decision-making, which may be used to inform clinical practice. Areas of nonconsensus were identified, highlighting uncertainty among the experts around some aspects of OCS use in asthma, such as adrenal insufficiency, which underscores the need for further research in these domains.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Suehs CM, Menzies-Gow A, Price D, et al. Expert Consensus on the Tapering of Oral Corticosteroids for the Treatment of Asthma. A Delphi Study. Am J Respir Crit Care Med. 2021. PMID: 33112646. doi:10.1164/rccm.202007-2721OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。